Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

NCT05223699 is registered in ClinicalTrials.gov with Magenta Therapeutics, Inc. as lead sponsor.

NCT NCT05223699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05223699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
Lead sponsor
Magenta Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 14, 2022
Completion date
February 2, 2023
Enrollment
22 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, myelodysplasia